
Abstracts include those evaluating Dupixent® (dupilumab) across six inflammatory diseases, including asthma, atopic dermatitis (AD), eosinophilic esophagitis (EoE), eosinophilic gastritis (EoG), chronic rhinosinusitis with nasal polyps (CRwNP) and chronic spontaneous urticaria (CSU) as well as rilzabrutinib in CSU.
Among the research highlights impacting asthma, Sanofi’s VESTIGE phase 4 trial could benefit uncontrolled, moderate-to-severe asthma. In this trial, Dupixent was associated with positive data on airway inflammation, mucus plugging, fractional exhaled nitric oxide (FeNO) and airway volume in patients with uncontrolled moderate-to-severe asthma.
A Sanofi late-breaking poster also will provide new insights into the effect of Dupixent on lung function and is the first study to use novel functional respiratory imaging to assess the effect of a biologic on lung function and airway volume. Additional oral presentations underscore the potential of Dupixent to transform the treatment paradigm for pediatric, adolescent and adult patients with eosinophilic esophagitis (EoE).
Specifically, Sanofi’s KIDS phase 3 trial has yielded positive, Dupixent data on histologic and endoscopic outcomes in children with EoE aged 1 through 11 years old at week 16 and through 52 weeks. Additional analysis was also presented on gene expression in these children. Similarly, its LIBERTY-EoE-TREET study has yielded positive Dupixent data on histologic, symptomatic and endoscopic aspects of EoE in adults and adolescents up to 52 weeks, regardless of prior elimination diet or food allergy.
In both instances, the safety results of these trials were generally consistent with the known safety profile of Dupixent.